This is just the beginning! Our collection holds over 300 years of history, including rare newspapers, obituaries, marriage records, birth records, and so much more—most of which you won’t find anywhere else!
Study finds orphan drug spending not harming overall costs
Health Affairs analysis of IMS Health data 2007 to 2013 on 300 plus orphan approved drugs shows spending rose from 4.8 to 8.9 percent of U.S. drug expenditures, totaling 15 to 30 billion dollars, with total health costs remaining the main concern. Researchers emphasize a linear spending trend due to more approvals, not runaway prices.
MENTIONED IN THIS ARTICLE
Health Affairs
Victoria Divine
IMS Health
Celgene
U.S
Clare Krusing
America’s Health Insurance Plans
National Association For Health Insurance Companies
AHIP
Revlimid
Evaluate Ltd
Divine
United States
Divino
Food and Drug Administration
Pharmaceutical
Phrma
Krusing
Johns Hopkins Medicine
American Journal of Clinical Oncology
Crestor
Humira
Martin Makary
Johns Hopkins School of Public Health
KHN
Laura and John Arnold Foundation
Kaiser Health News
Henry J. Kaiser Family Foundation